Abstract
Purpose of ReviewThe purpose of the study is to provide health care providers with general overview of the novel treatment strategies for patients infected with hepatitis C virus (HCV), monitoring for drug interactions, and dose modification in patients with renal impairment.Recent FindingsThe rapidly increasing demand for HCV infection treatment and the side effects associated with ribavirin (RBV) and peginterferon regimens led to the development of the novel direct acting antivirals (DAAs) and are RBV/peginterferon-free treatment in most cases. Several combinations, RBV-free regimens with different durations of therapy, were recently approved for patients with DAAs failure.SummaryTreatment regimen and duration are based on the genotype (GT), presence of cirrhosis, presence of resistance, and history of treatment. Some DAAs required dose modification and monitoring in patients with renal impairment or with the new start of interacting medications. Close monitoring, dose modification, or discontinuation is required for co-administration of interacting medications.